Bactiguard announced strengthened ties with Becton Dickinson. An interim agreement has been signed granting BD an exclusive global license, effective immediately, for Bactiguard coated Foley catheters, which is a first step on the strategy of phasing-out Bactiguard’s medical device portfolio. The interim agreement to extend the partnership with BD includes sales exclusivity of Foleys not only in the US, Japan, UK, Canada, Ireland, and Australia, but now also the rest of the world and aims at limiting supply disruptions for current distributors and customers. The majority will be offered Bactiguard coated BD Foley catheters which have similar features and functionality to the Bactiguard Foley. It is both parties’ expectations to enter into an expanded long-term license agreement during the first half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Becton Dickinson price target lowered to $280 from $310 at Morgan Stanley
- Becton Dickinson reports FDA safety communication doesn’t impact BD syringes
- Becton Dickinson names Ronald Silverman chief medical officer
- Becton Dickinson earnings selloff a buying opportunity, says Barclays
- Becton Dickinson price target lowered to $280 from $305 at Piper Sandler